Sanofi wins tentative FDA nod for Admelog insulin lispro injection

Sanofi (NYSE:SNY) said today that the FDA granted the company tentative approval for its Admelog insulin lispro injection.

The decision is based on physicochemical, non-clinical and clinical similarity to another, already-approved insulin lispro injection. The compound is contraindicated during hypoglycemia episodes and in patients with hypersensitivity to insulin lispro or one of its other ingredients, Sanofi said.

Get the full story at our sister site, Drug Delivery Business News.

The post Sanofi wins tentative FDA nod for Admelog insulin lispro injection appeared first on MassDevice.

from MassDevice http://ift.tt/2eqjrQf